Aligos Therapeutics Announces $105 Million Private Placement Financing
Aligos Therapeutics (NASDAQ: ALGS) has secured a $105 million private placement financing, led by a life sciences dedicated investment firm with participation from new and existing institutional investors. The company is selling 2,103,307 shares of common stock (1,427,000 voting and 676,307 non-voting), pre-funded warrants for up to 1,922,511 voting shares, and warrants for up to 2,012,909 voting shares.
The combined price is $26.0825 per share of common stock and accompanying warrant, with pre-funded warrants priced at $26.0824. The warrants will have an exercise price of $26.02 per share and will expire on February 13, 2032. The proceeds will fund the ALG-000184 Phase 2 clinical study in chronic hepatitis B virus infection and extend the company's cash runway into the second half of 2026.
Aligos Therapeutics (NASDAQ: ALGS) ha ottenuto un finanziamento privato di 105 milioni di dollari, guidato da una società di investimento dedicata alle scienze della vita, con la partecipazione di nuovi e vecchi investitori istituzionali. L'azienda sta vendendo 2.103.307 azioni ordinarie (1.427.000 azioni con diritto di voto e 676.307 azioni senza diritto di voto), warrant pre-finanziati per un massimo di 1.922.511 azioni con diritto di voto e warrant per un massimo di 2.012.909 azioni con diritto di voto.
Il prezzo combinato è di 26,0825 dollari per azione ordinaria e warrant associato, con i warrant pre-finanziati valutati a 26,0824 dollari. I warrant avranno un prezzo di esercizio di 26,02 dollari per azione e scadranno il 13 febbraio 2032. I proventi finanzieranno lo studio clinico di fase 2 ALG-000184 per l'infezione cronica da virus dell'epatite B e estenderanno la liquidità dell'azienda fino alla seconda metà del 2026.
Aligos Therapeutics (NASDAQ: ALGS) ha asegurado un financiamiento de colocación privada de 105 millones de dólares, liderado por una firma de inversión dedicada a las ciencias de la vida, con la participación de nuevos y existentes inversores institucionales. La compañía está vendiendo 2,103,307 acciones comunes (1,427,000 con derecho a voto y 676,307 sin derecho a voto), warrants prefinanciados por hasta 1,922,511 acciones con derecho a voto y warrants por hasta 2,012,909 acciones con derecho a voto.
El precio combinado es de 26.0825 dólares por acción común y el warrant asociado, con warrants prefinanciados valorados en 26.0824 dólares. Los warrants tendrán un precio de ejercicio de 26.02 dólares por acción y vencerán el 13 de febrero de 2032. Los ingresos financiarán el estudio clínico de fase 2 ALG-000184 para la infección crónica por el virus de la hepatitis B y extenderán la liquidez de la empresa hasta la segunda mitad de 2026.
Aligos Therapeutics (NASDAQ: ALGS)는 생명 과학에 전념하는 투자 회사가 주도하고 새로운 기관 투자자와 기존 투자자가 참여한 1억 500만 달러의 사모 펀딩을 확보했습니다. 이 회사는 2,103,307주의 보통주(1,427,000주 투표권 있는 주식 및 676,307주 투표권 없는 주식), 최대 1,922,511주의 투표권 있는 주식에 대한 사전 자금 조달 워런트, 최대 2,012,909주의 투표권 있는 주식에 대한 워런트를 판매하고 있습니다.
결합 가격은 보통주와 동반되는 워런트당 26.0825달러이며, 사전 자금 조달 워런트 가격은 26.0824달러입니다. 워런트의 행사가격은 주당 26.02달러이며 2032년 2월 13일에 만료됩니다. 수익금은 ALG-000184 2상 임상 연구를 만성 B형 간염 바이러스 감염에 대한 자금을 지원하고 회사의 자금 운영을 2026년 하반기까지 연장하는 데 사용됩니다.
Aligos Therapeutics (NASDAQ: ALGS) a sécurisé un financement de placement privé de 105 millions de dollars, dirigé par une société d'investissement dédiée aux sciences de la vie, avec la participation de nouveaux investisseurs institutionnels et d'investisseurs existants. L'entreprise vend 2 103 307 actions ordinaires (1 427 000 avec droit de vote et 676 307 sans droit de vote), des bons de souscription préfinancés pour un maximum de 1 922 511 actions avec droit de vote, et des bons de souscription pour un maximum de 2 012 909 actions avec droit de vote.
Le prix combiné est de 26,0825 dollars par action ordinaire et bon de souscription associé, les bons de souscription préfinancés étant au prix de 26,0824 dollars. Les bons de souscription auront un prix d'exercice de 26,02 dollars par action et expireront le 13 février 2032. Les produits financeront l'
Aligos Therapeutics (NASDAQ: ALGS) hat eine Privatplatzierungsfinanzierung in Höhe von 105 Millionen Dollar gesichert, die von einer auf Lebenswissenschaften spezialisierten Investmentfirma geleitet wird, mit Beteiligung neuer und bestehender institutioneller Investoren. Das Unternehmen verkauft 2.103.307 Stammaktien (1.427.000 stimmberechtigte und 676.307 nicht stimmberechtigte Aktien), vorfinanzierte Warrants für bis zu 1.922.511 stimmberechtigte Aktien und Warrants für bis zu 2.012.909 stimmberechtigte Aktien.
Der kombinierte Preis beträgt 26,0825 Dollar pro Stammaktie und zugehörigem Warrant, wobei die vorfinanzierten Warrants zu 26,0824 Dollar bewertet werden. Die Warrants haben einen Ausübungspreis von 26,02 Dollar pro Aktie und laufen am 13. Februar 2032 aus. Die Erlöse werden die ALG-000184 Phase 2 klinische Studie zur chronischen Hepatitis-B-Virusinfektion finanzieren und die Liquidität des Unternehmens bis in die zweite Hälfte des Jahres 2026 verlängern.
- Secured substantial $105 million financing
- Cash runway extended into second half of 2026
- Advancement to Phase 2 clinical study for ALG-000184
- Potential dilution for existing shareholders through new share issuance
- Warrants could lead to additional future dilution
Insights
This $105 million private placement represents a strategic financing move that significantly strengthens Aligos's position. The pricing at $26.0825 per share, essentially at market value, signals strong institutional confidence in the company's prospects, particularly noteworthy in the current biotech funding environment.
The financing structure is sophisticated and shareholder-friendly. The inclusion of both voting and non-voting shares (1,427,000 voting and 676,307 non-voting) helps maintain current governance structures while raising capital. The pre-funded warrants, with their nominal
The extended cash runway into H2 2026 provides important operational flexibility, particularly important for clinical-stage biotech companies. This timeline suggests sufficient funding for the critical Phase 2 study of ALG-000184, eliminating near-term financing pressure and allowing management to focus on clinical execution.
The warrant component, exercisable until 2032 at
The participation of both new and existing institutional investors, led by a life sciences dedicated firm, provides strong validation of Aligos's clinical programs and strategy. The involvement of established placement agents like Jefferies and Piper Sandler adds further credibility to the transaction.
Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study
Funding expected to extend cash runway into the second half of 2026
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately
The private placement is being led by a life sciences dedicated investment firm with participation from other new and existing institutional investors.
Aligos currently expects to use the net proceeds from the private placement, together with its existing cash, cash equivalents and investments, to fund the continued advancement of ALG-000184 into a Phase 2 clinical study in subjects with chronic hepatitis B virus infection (CHB) and for other general corporate purposes.
Aligos believes its cash, cash equivalents and investments, including the expected net proceeds from the private placement, will provide sufficient funding of planned operations into the second half of 2026.
In the private placement, Aligos is selling 2,103,307 shares of common stock, consisting of 1,427,000 shares of voting common stock and 676,307 shares of non-voting common stock, pre-funded warrants to purchase up to 1,922,511 shares of voting common stock, and accompanying warrants to purchase up to 2,012,909 shares of voting common stock at a combined price per share of common stock and accompanying warrant of
Jefferies and Piper Sandler are acting as placement agents for the private placement. H.C. Wainwright & Co. is acting as financial advisor in connection with the transaction.
The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Aligos granted registration rights to the purchasers in private placements, and has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement, the shares of common stock issuable upon exercise of the pre-funded warrants issued in the private placement and the shares of common stock issuable upon exercise of the accompanying warrants issued in the private placement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for diseases with high unmet medical need such as chronic hepatitis B virus infection (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements related to the sufficiency of funding of planned operations, the expected use of proceeds of the financing, the timing and expectation of the closing of the private placement. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
FAQ
How much funding did Aligos Therapeutics (ALGS) raise in the February 2025 private placement?
What is the exercise price of the warrants issued in ALGS's 2025 private placement?
How long will the 2025 private placement funding extend ALGS's cash runway?
What will ALGS use the proceeds from the 2025 private placement for?
How many shares is ALGS selling in the February 2025 private placement?
